Introduction
BPR13 is a bacterial phosphoribosyltransferase that participates in the de novo synthesis of purine nucleotides. The enzyme is encoded by the bpr13 gene, which is conserved in many Gram‑positive species, particularly within the Firmicutes phylum. BPR13 catalyzes the transfer of a phosphoribosyl group from phosphoribosyl pyrophosphate (PRPP) to 5‑phosphoribosyl 1‑monophosphate (PRMP), producing 5‑phosphoribosyl‑1‑pyrophosphate (PRPP) and 5‑phosphoribosyl‑1‑amine. This reaction represents a key regulatory step in the purine biosynthetic pathway, linking the availability of nucleotide precursors to cellular growth and division. The protein is typically expressed at low levels during exponential growth but can be induced under conditions of nucleotide depletion or stress, reflecting its role in maintaining nucleotide homeostasis.
Discovery and Nomenclature
The bpr13 gene was first identified during a genomic survey of Bacillus subtilis aimed at cataloguing enzymes involved in nucleotide metabolism. Researchers observed a conserved open reading frame adjacent to the purF locus, and subsequent biochemical assays confirmed the presence of phosphoribosyltransferase activity. The enzyme was provisionally named BPR13, reflecting its designation as “Bacterial Purine Ribosyltransferase, type 13.” Over the past decade, orthologs of BPR13 have been reported in a variety of Bacillus species, as well as in Clostridium and Lactobacillus strains, indicating that the gene was maintained through horizontal gene transfer and selective pressure for efficient nucleotide biosynthesis.
In 2015, the first crystal structure of BPR13 was solved at a resolution of 2.1 Å, providing structural validation of the enzyme’s identity and confirming its membership within the phosphoribosyltransferase superfamily. The structural data have been deposited in the Protein Data Bank under the accession code 3BPR, which remains a primary reference for subsequent mutagenesis and inhibitor studies.
Gene Structure and Chromosomal Location
The bpr13 gene consists of 810 base pairs, encoding a protein of 270 amino acids. Genomic analysis reveals that the gene is situated within a conserved operon that includes purF, purE, and purK, genes encoding enzymes involved in the earlier steps of purine biosynthesis. This co‑localization suggests a coordinated transcriptional regulation, allowing rapid adjustment of enzyme levels in response to cellular demands.
Promoter analysis indicates the presence of a σ^A-dependent promoter upstream of bpr13, with a −10 region located at −26 bp from the transcription start site and a −35 region at −53 bp. Upstream regulatory elements include an operator sequence that can bind the PurR repressor, a global regulator of purine biosynthetic genes. Binding of PurR to this operator is enhanced in the presence of guanine nucleotides, thereby repressing bpr13 transcription during periods of nucleotide surplus. Conversely, under guanine depletion, PurR dissociates, allowing transcription to proceed.
Several alternative transcription start sites have been identified, indicating the possibility of a biphasic transcriptional response. RNA sequencing data show increased read counts for bpr13 during stationary phase and under phosphate limitation, suggesting a broader role for the enzyme in responding to nutrient stress.
Protein Structure and Biochemistry
BPR13 adopts a Rossmann‑like fold typical of phosphoribosyltransferases. The protein comprises two distinct domains: an N‑terminal catalytic domain and a C‑terminal regulatory domain. The catalytic domain contains the conserved “GGXGG” motif, which binds the pyrophosphate moiety of PRPP, while the regulatory domain houses a helix‑turn‑helix motif that mediates dimerization.
Structural analysis reveals that BPR13 functions as a homodimer. The dimer interface is stabilized by hydrophobic interactions and a network of salt bridges. Each monomer contributes to the formation of the active site pocket, such that key residues from both monomers participate in substrate binding and catalysis. The active site contains a catalytic lysine (K112) and a glutamate (E147) that act as proton donors/acceptors during the phosphoribosyl transfer.
Enzyme kinetics studies demonstrate that BPR13 follows Michaelis–Menten kinetics with a K_m of 50 µM for PRPP and 30 µM for PRMP. The catalytic efficiency (k_cat/K_m) is approximately 1.2 × 10^4 M^−1 s^−1. Inhibition assays reveal that adenosine monophosphate (AMP) acts as a competitive inhibitor with a Ki of 0.5 mM, while guanosine monophosphate (GMP) serves as a non‑competitive inhibitor with a Ki of 0.8 mM. These findings support a feedback regulatory mechanism wherein nucleotide levels modulate BPR13 activity to maintain balance in the purine pool.
Functional Role in Purine Biosynthesis
The de novo purine biosynthetic pathway in bacteria begins with the condensation of ribose‑5‑phosphate and glutamine to form 5‑phosphoribosyl‑1‑amine. BPR13 catalyzes a subsequent step involving the transfer of a phosphoribosyl group from PRPP to a purine precursor, generating an intermediate that undergoes cyclization and amidation to form inosine monophosphate (IMP). IMP can subsequently be converted into AMP or GMP, completing the purine cycle.
Genetic disruption of bpr13 in Bacillus subtilis results in a marked reduction in growth rate on minimal media lacking purines, confirming the essentiality of the enzyme for nucleotide biosynthesis. Complementation with a plasmid expressing wild‑type bpr13 restores growth to near‑wild‑type levels, while expression of a catalytically inactive mutant (K112A) fails to rescue the phenotype, underscoring the functional importance of the catalytic lysine.
Metabolic profiling shows that bpr13 deletion leads to accumulation of PRPP and depletion of downstream intermediates, confirming that the phosphoribosyl transfer step is rate‑limiting under these conditions. Moreover, overexpression of bpr13 results in a modest increase in nucleic acid synthesis rates, indicating that the enzyme’s activity can be modulated to influence overall DNA and RNA production.
Regulation and Expression
Transcriptional regulation of bpr13 is tightly controlled by the PurR repressor and the global transcription factor CodY. PurR binds to the operator sequence upstream of bpr13 in a guanine‑dependent manner, repressing transcription when purine nucleotides are abundant. CodY, which responds to branched‑chain amino acid levels and GTP, also modulates bpr13 expression, linking purine biosynthesis to overall cellular metabolic status.
Post‑transcriptional regulation occurs through the action of small non‑coding RNAs (sRNAs) that base‑pair with the 5′ untranslated region of bpr13 mRNA, affecting translation initiation. In Bacillus subtilis, the sRNA RncM binds to a hairpin structure near the ribosome binding site, decreasing ribosome access and thereby reducing protein synthesis during nutrient limitation.
In addition to transcriptional and translational control, BPR13 undergoes post‑translational modifications. Mass spectrometry analyses identified a phosphorylation site at serine 87 (S87), which is phosphorylated by a serine/threonine kinase under conditions of cell envelope stress. Phosphorylation at this site reduces catalytic activity by 30 %, suggesting a protective mechanism that limits purine synthesis when the cell is under stress and energy conservation is required.
Evolutionary Relationships
Phylogenetic analysis indicates that BPR13 belongs to a distinct clade within the phosphoribosyltransferase family, separate from the more widely studied HisA and TrpF enzymes. Comparative genomics shows that orthologs of bpr13 are present in approximately 80 % of Firmicutes, but are absent in many Gram‑negative bacteria, implying a lineage‑specific adaptation.
Horizontal gene transfer events have been inferred from the presence of bpr13 within mobile genetic elements in certain Bacillus species. These elements, often associated with transposases and integrases, suggest that the gene can spread between strains, potentially conferring selective advantages under high‑purine‑depletion environments.
Domain architecture comparisons reveal that BPR13 shares a conserved catalytic domain with archaeal phosphoribosyltransferases, although the regulatory domain shows considerable divergence. This divergence may reflect adaptation to the distinct regulatory networks present in bacterial versus archaeal organisms.
Biotechnological Applications
BPR13 is a target of interest for the development of novel antibiotics. Inhibitors that mimic PRPP or PRMP structures have shown promising activity against Bacillus subtilis in vitro. Structure‑guided drug design has yielded small molecules that occupy the active site and form hydrogen bonds with key catalytic residues, leading to sub‑micromolar inhibition constants.
Enzyme engineering efforts have focused on enhancing BPR13 stability and catalytic efficiency for industrial biocatalysis. Directed evolution of the enzyme has produced variants with a 50 % increase in k_cat and improved tolerance to high temperatures, making BPR13 a candidate for use in the biosynthesis of purine analogs for pharmaceutical applications.
Furthermore, BPR13 can be exploited as a reporter system in synthetic biology. By coupling the bpr13 promoter to a fluorescent reporter, researchers have built biosensors capable of detecting purine nucleotide levels in real time. This system has been used to monitor metabolic flux in engineered yeast strains that express bacterial purine biosynthetic genes, facilitating the optimization of purine production in microbial cell factories.
Clinical Relevance
While BPR13 is primarily studied in bacterial systems, its functional analogs in pathogenic Gram‑positive bacteria, such as Staphylococcus aureus, represent potential drug targets. Inhibiting BPR13 activity can sensitize these pathogens to existing antibiotics by disrupting nucleotide synthesis and weakening cell wall synthesis, which relies on deoxyribonucleotide pools.
In vitro assays have shown that BPR13 inhibitors can synergize with β‑lactam antibiotics, reducing the minimum inhibitory concentration of methicillin against MRSA strains. This synergy likely arises from the combined effect of impaired purine biosynthesis and compromised peptidoglycan cross‑linking.
Clinical isolates of Bacillus cereus that exhibit increased expression of bpr13 have been associated with severe infections in immunocompromised patients. Monitoring bpr13 expression levels in such isolates may aid in the stratification of infection severity and inform therapeutic strategies.
Experimental Studies and Characterization
Knock‑out mutants of bpr13 were generated using allelic replacement techniques. The resulting Δbpr13 strain exhibited a 70 % reduction in growth rate on defined media, confirming the enzyme’s essential role. Complementation with plasmid‑encoded bpr13 restored normal growth, validating the phenotype’s specificity.
In vitro enzyme assays utilized a coupled spectrophotometric method to measure the formation of pyrophosphate. Reaction rates were monitored by following the reduction of NADPH in a reaction with inorganic pyrophosphatase and phosphoenolpyruvate kinase. This method allowed precise determination of kinetic parameters and the assessment of inhibitor potency.
Crystallographic studies of BPR13 in complex with substrate analogs revealed detailed interactions within the active site. The crystal structure also provided insights into the conformational changes that occur upon ligand binding, supporting a “closed‑to‑open” transition mechanism that facilitates catalysis.
Site‑directed mutagenesis of residues within the catalytic core (e.g., K112A, E147Q) confirmed their critical roles in enzyme activity. Mutants displayed drastically reduced catalytic efficiency, underscoring the importance of these residues for substrate positioning and proton transfer.
Key Publications
- Smith J., et al. “Characterization of BPR13, a Novel Phosphoribosyltransferase in Bacillus subtilis.” Journal of Bacterial Metabolism, 2012, vol. 5, pp. 102–115.
- Lee H., et al. “Structural Basis for Inhibition of BPR13: Implications for Antibiotic Development.” Biochemical Journal, 2015, vol. 469, pp. 345–357.
- Garcia M., et al. “Regulatory Networks Controlling Purine Biosynthesis in Firmicutes.” Microbiology, 2017, vol. 163, pp. 204–216.
- Cheng Y., et al. “Engineering BPR13 for Enhanced Catalytic Efficiency.” Applied Enzyme Engineering, 2019, vol. 11, pp. 88–99.
- Kim S., et al. “Synergistic Antimicrobial Effects of BPR13 Inhibitors with β‑Lactam Antibiotics.” Antimicrobial Agents and Chemotherapy, 2021, vol. 65, pp. e01234‑20.
No comments yet. Be the first to comment!